Pelthos Therapeutics Inc. PTHS 深 沪
等待开盘 05-13 09:30:00 美东时间
27.24
+0.390
+1.45%
华盛通- 最 高27.48
- 今 开27.3784
- 成交量 8631股
- 最 低 26.65
- 昨 收 26.85
- 总市值 9140.50万
- 52周最高 54.29
- 市盈率 静 --
- 换手率 0.26%
- 52周最低 9.00
- 委 比 -98.02%
- 总股本 335.55万
- 历史最高 60.00
- 量 比 0.33
- 振 幅 3.09%
- 历史最低 4.50
- 每 手 1
- 风险率 6.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pelthos Highlights Infectious Disease Portfolio at Investor Meetings
An update from Pelthos Therapeutics ( ($PTHS) ) is now available. Pelthos Thera...
04-14 21:07
Pelthos CEO to hold investor meetings at Piper Sandler Spring Biopharma Symposium
Pelthos CEO to hold investor meetings at Piper Sandler Spring Biopharma Symposium Pelthos Therapeutics CEO Scott Plesha will hold one-on-one investor meetings at Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston. Disclaimer: This news brief was created by Public Technologies (PUBT
04-14 20:36
Pelthos Therapeutics Appoints John M. Gay As CFO
Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced John M. Gay has been appointed Chief
04-11 05:22
Pelthos Therapeutics names John M. Gay as CFO
Pelthos Therapeutics (PTHS) announced on Friday the appointment of John M. Gay as CFO, effective April 10, 2026, succeeding Francis Knuettel II. Gay brings over 25 years of public company finance and ...
04-11 05:11
Pelthos Therapeutics Announces First Patient Dosed In Phase 1b/2a Clinical Trial Evaluating CT2000 As Potential Treatment For Eye Pain
First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye diseaseCT2000 is a lead pipeline asset of
03-31 20:31
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
Pelthos Therapeutics Inc. has initiated a Phase 1b/2a clinical trial to evaluate CT2000, a NaV1.7 inhibitor, as a potential treatment for acute and chronic ocular pain associated with dry eye disease. CT2000, a lead asset of Pelthos subsidiary Channel Therapeutics, has shown promise in preclinical studies targeting eye pain caused by conditions like severe dry eye disease. The trial, conducted in Australia, will assess safety and efficacy in pati...
03-31 12:30
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
Earnings Scheduled For March 19, 2026
Companies Reporting Before The Bell • Neuraxis (AMEX:NRXS) is projected to repo...
03-19 19:11
